Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.30 USD

28.30
36,958,246

-0.22 (-0.77%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $28.34 +0.04 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk

Sanghamitra Saha headshot

Goldman Fans Can Reap Returns From S&P 500 ETFs in 2022

Goldman Sachs (GS) this week said that it expects the S&P 500 to rise 9% to 5,100 by the end of 2022, as quoted on a Yahoo Finance article.

Atea (AVIR) Plunges on Termination of Collaboration With Roche

Atea (AVIR) stock falls on termination of collaboration with Roche for the development of oral drug for the treatment of COVID-19.

Pfizer (PFE) Seeks FDA's Emergency Use Nod for COVID Pill

Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially in mild-to-moderate COVID-19 patients at increased risk of hospitalizations or death.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Kinjel Shah headshot

3 Big Pharma Outperformers to Watch Out For in the Near Term

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

4 Reasons Why You Should Add Glaxo (GSK) to Your Portfolio

Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2021/2022, which should boost the top line in the long term

Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing

Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.

J&J (JNJ) to Separate Consumer Unit Into New Company, Stock Up

J&J (JNJ) is set to divide itself into two publicly traded companies. One will be its consumer products, while the other will comprise its pharmaceuticals and medical devices segments.

Pre-Markets Edge Up on JNJ Split News

Pre-Markets Edge Up on JNJ Split News

Mark Vickery headshot

J&J Plans to Split in Two; Dow Up Triple Digits

In order to focus on market growth in its Pharma division, Johnson & Johnson now plans to split its Consumer Health business into a separate entity.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, BAYRY Q3 Results, PFE COVID Pill's Strong Efficacy

AstraZeneca (AZN) and Bayer (BAYRY) announce Q3 results. Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially.

Merck (MRK) Inks $1.2B COVID-19 Pill Supply Deal With Japan

Japan's government is set to purchase 1.6 million courses of Merck's (MRK) oral pill for COVID-19, molnupiravir, if approved or authorized.

Valneva (VALN) Stock Rises on Deal With EU for COVID-19 Jab

Valneva (VALN) enters into a supply agreement for its COVID vaccine candidate with the European Commission. The stock price surges following the news.

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer

Biotech Stock Roundup: REGN, MRNA Post Q3 Earnings, SAVA Gains on AD Review Data

Earnings and other updates from bigwigs like Regeneron (REGN) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.

Sweta Killa headshot

7 Stocks With Triple-Digit Gains Powering S&P 500 ETF

The S&P 500 logged in eight consecutive gains, representing its longest winning streak since 2017, and closed above the 4,700 milestone for the first time ever.

Daniel Laboe headshot

The Stock Market Rally Is Back In High Gear

All the major indexes are trading at record levels, but how long can this rally hold us in this extremely overbought state?

Is a Beat in Store for BioNTech (BNTX) This Earnings Season?

On BioNTech's (BNTX) third-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.

Sweta Killa headshot

5 ETFs Sizzling to Start November

ETFs overall gathered about $20 billion capital last week (ending Nov 5), bringing in inflows of more than $739 billion year to date.

Pfizer (PFE) COVID Pill Shows Strong Efficacy, Stock Rallies

Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially

Markets Up on COVID Pill News

Markets Up on COVID Pill News

Mark Vickery headshot

More Good Covid Treatment News; Markets Up Again

The Dow is +140 points, the S&P 500 +10 and the Nasdaq +2 points in the pre-market.

Sweta Killa headshot

Rally in Travel and Tourism ETFs Set to Continue

The solid trend in travel and tourism ETFs are likely to continue heading into the holiday season given the reopening of domestic and international borders for traveling.

Stock Market News for Nov 8, 2021

Benchmarks closed higher on Friday lifted by solid October jobs report and encouraging COVID-19 antiviral drug results from Pfizer.